SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
Anna M Knapinska, Daniela Dreymuller, Andreas Ludwig, Lyndsay Smith, Vladislav Golubkov, Anjum Sohail, Rafael Fridman, Marc Giulianotti, Travis M LaVoi, Richard A Houghten, Gregg B Fields, Dmitriy Minond
Index: J. Med. Chem. 58 , 5808-24, (2015)
Full Text: HTML
Abstract
ADAM17 is implicated in several debilitating diseases. However, drug discovery efforts targeting ADAM17 have failed due to the utilization of zinc-binding inhibitors. We previously reported discovery of highly selective nonzinc-binding exosite-targeting inhibitors of ADAM17 that exhibited not only enzyme isoform selectivity but synthetic substrate selectivity as well ( J. Biol. Chem. 2013, 288, 22871). As a result of SAR studies presented herein, we obtained several highly selective ADAM17 inhibitors, six of which were further characterized in biochemical and cell-based assays. Lead compounds exhibited low cellular toxicity and high potency and selectivity for ADAM17. In addition, several of the leads inhibited ADAM17 in a substrate-selective manner, which has not been previously documented for inhibitors of the ADAM family. These findings suggest that targeting exosites of ADAM17 can be used to obtain highly desirable substrate-selective inhibitors. Additionally, current inhibitors can be used as probes of biological activity of ADAM17 in various in vitro and, potentially, in vivo systems.
Related Compounds
Related Articles:
Permeation of Dopamine Sulfate through the Blood-Brain Barrier.
2015-01-01
[PLoS ONE 10 , e0133904, (2015)]
Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals.
2015-01-01
[Nat. Commun. 6 , 8716, (2015)]
2015-11-13
[Eur. J. Med. Chem. 105 , 63-79, (2015)]
2015-09-01
[Bioorg. Med. Chem. 23 , 5402-9, (2015)]
2015-08-01
[Pharm. Res. 32 , 2713-26, (2015)]